Cytokeratin and CD56 aberrant co-expression in diffuse large B-cell lymphoma, NOS misinterpreted as metastatic neuroendocrine carcinoma by FNAC

Veronika Kloboves Prevodnik; Gorana Gašljević

doi:10.1111/cyt.13190

Cytokeratin and CD56 aberrant co-expression in diffuse large B-cell lymphoma, NOS misinterpreted as metastatic neuroendocrine carcinoma by FNAC

Cytopathology. 2023 Mar;34(2):165-168. doi: 10.1111/cyt.13190. Epub 2022 Dec 7.

Authors

Veronika Kloboves Prevodnik¹, Gorana Gašljević²

Affiliations

¹ Department of Cytopathology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
² Department of Pathology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.

Abstract

Aberrant expression of epithelial and neuroendocrine markers is rare in diffuse large B-cell lymphoma (DLBCL) and can lead to erroneous diagnosis with inappropriate treatment. This case report describes a case of DLBCL with a co-expression of cytokeratins and CD56 that was misdiagnosed as metastatic neuroendocrine carcinoma.

Publication types

Case Reports

MeSH terms

CD56 Antigen / metabolism
Carcinoma, Neuroendocrine* / diagnosis
Carcinoma, Neuroendocrine* / genetics
Humans
Immunophenotyping
Keratins / genetics
Lymphoma, Large B-Cell, Diffuse* / diagnosis
Lymphoma, Large B-Cell, Diffuse* / pathology

Substances

Keratins
CD56 Antigen